Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

130
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
130
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

69
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
69
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

106
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
106
Nephrons01:10

Nephrons

3.6K
The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma...
3.6K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

41
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
41
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

128
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
128

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of serum autoantibodies in lupus nephritis.

Autoimmunity reviews·2026
Same author

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same author

Cardiac involvement in Behçet's syndrome: findings from a clinically driven cardiological evaluation.

Rheumatology (Oxford, England)·2026
Same author

EGPAware: a European Delphi consensus study on red flags for suspicion of eosinophilic granulomatosis with polyangiitis.

EULAR rheumatology open·2026
Same author

'Veni, Vidi, Vaccini': consensus-based vaccination pathway implementation in a paediatric tertiary hospital in Tuscany, Italy.

European journal of public health·2026
Same author

Glomeruloid haemangioma in Erdheim-Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor-A levels.

British journal of haematology·2026

Related Experiment Video

Updated: Sep 29, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.5K

Type I interferon-related kidney disorders.

Lorenzo Lodi1, Maria V Mastrolia2, Federica Bello3

  • 1Department of Health Sciences, University of Firenze, Firenze, Italy; Immunology Unit, Department of Pediatrics, Meyer Children's Hospital, Firenze, Italy.

Kidney International
|March 27, 2022
PubMed
Summary
This summary is machine-generated.

Type I interferon (IFN-I) damages kidneys in various disorders by affecting renal cells. Understanding these IFN-I-related kidney diseases is crucial for developing targeted therapies.

Keywords:
collapsing glomerulopathyglomerulonephritisinterferoninterferonopathysystemic lupus erythematosusviral nephropathy

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

818

Related Experiment Videos

Last Updated: Sep 29, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.5K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
04:37

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis

Published on: April 25, 2025

818

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • Type I interferon (IFN-I) plays a key role in kidney damage across diverse renal disorders.
  • Enhanced IFN-I signaling is implicated in viral infections, autoimmune diseases like lupus, and genetic type 1 interferonopathies.
  • These conditions share common pathogenic and histopathological features, leading to renal dysfunction.

Purpose of the Study:

  • To elucidate the role of Type I interferon in kidney pathology.
  • To define the nosology, pathogenic mechanisms, and histopathological patterns of IFN-I-related kidney disorders.
  • To highlight the diagnostic and therapeutic implications for emerging treatments targeting the IFN-I pathway.

Main Methods:

  • Review of literature on IFN-I-related kidney disorders.
  • Analysis of pathogenic mechanisms and histopathological features.
  • Correlation of clinical presentations with IFN-I signaling pathways.

Main Results:

  • IFN-I directly impacts renal cells, including podocytes, mesangial, endothelial, and parietal epithelial cells.
  • Collapsing glomerulopathy is a key lesion associated with IFN-I, particularly affecting podocytes and parietal epithelial cells.
  • IFN-I contributes to immune-mediated glomerular injury and vascular lesions (e.g., thrombotic microangiopathy, vasculitis) in various kidney diseases.

Conclusions:

  • Type I interferon is a central mediator of kidney damage in a spectrum of diseases.
  • Podocytes and parietal epithelial cells are primary targets of IFN-I-induced injury.
  • A comprehensive understanding of IFN-I-related nephropathies is essential for future therapeutic strategies.